Coadministration of Vascular Disrupting Agents and Nanomedicines to Eradicate Tumors from Peripheral and Central Regions
Abstract
A strategy for enhancing the treatment efficacy of nanomedicines within the central region of solid tumors is developed by combining nanomedicines and free small‐molecule vascular disrupting agents (VDAs). The nanomedicines (cis‐diamminedichloroplatinum–loaded nanoparticles) primarily target cells at the tumor periphery whereas the free small‐molecule VDA (combretastatin A4 disodium phosphate) efficiently kills the cancer cells within the central regions of the tumor.Keywords
This publication has 41 references indexed in Scilit:
- Phase I Safety, Pharmacokinetic and Pharmacodynamic Evaluation of the Vascular Disrupting Agent Ombrabulin (AVE8062) in Patients with Advanced Solid TumorsClinical Cancer Research, 2013
- Fast Multispectral Optoacoustic Tomography (MSOT) for Dynamic Imaging of Pharmacokinetics and Biodistribution in Multiple OrgansPLOS ONE, 2012
- Targeted drug delivery to tumors: Myths, reality and possibilityJournal of Controlled Release, 2011
- The development of the tumor vascular-disrupting agent ASA404 (vadimezan, DMXAA): current status and future opportunitiesExpert Opinion on Investigational Drugs, 2010
- Mediating Tumor Targeting Efficiency of Nanoparticles Through DesignNano Letters, 2009
- A review and update of the current status of the vasculature-disabling agent combretastatin-A4 phosphate (CA4P)Expert Opinion on Investigational Drugs, 2009
- Nanoparticle therapeutics: an emerging treatment modality for cancerNature Reviews Drug Discovery, 2008
- Phase I clinical evaluation of ZD6126, a novel vascular-targeting agent, in patients with solid tumorsInvestigational New Drugs, 2008
- Comparison of tumor blood perfusion assessed by dynamic contrast-enhanced MRI with tumor blood supply assessed by invasive imagingJournal of Magnetic Resonance Imaging, 2005
- Pharmacokinetics of Pegylated Liposomal DoxorubicinClinical Pharmacokinetics, 2003